Optum grows limited distribution drug network, expanding opportunity to serve more patients with complex and rare diseases
November 18, 2025 | 2-minute read
When a child urgently needed access to Mesoblast’s Ryoncil, a specialty medication, Optum Frontier Therapies delivered. As the exclusive specialty pharmacy for this cell therapy, the team ensured the medication arrived within days. For one of the most vulnerable patient populations, this wasn’t just a delivery; it was a lifeline.
Delivering specialty medications with care, speed and trust
This moment reflects the power of Optum Frontier Therapies’ pharmacy model. Limited distribution drugs (LDDs) are high-cost, high-touch medications selected by manufacturers for distribution through a limited network due to their complexity or handling requirements. Optum Frontier Therapies’ clinical expertise and operational reliability make it a preferred partner for manufacturers – like Mesoblast – seeking a trusted partner that can deliver quality care and help track longitudinal outcomes that show the efficacy of their drug.
By the numbers
Today, Optum has access to more than 200 LDDs and continues to expand. In 2025 alone, Optum was awarded access to 12 new LDDs across its pharmacy network – including Optum Specialty Pharmacy, Optum Frontier Therapies, Optum Infusion Pharmacy and Genoa Healthcare*. With real-time data and a commitment to seamless coordination, Optum is helping more patients get the therapies they need, when they need them most. This includes:
The bottom line: These therapies span a range of conditions and treatment modalities, supported by Optum’s multidisciplinary teams. To learn more about Optum’s pharmacies and new drug approvals, visit Optum’s pharmacy drug approval page.
Related news
News story
Learn how Optum Infusion Pharmacy supported one patient living with a neurologic condition.
May 28, 2026
Press release
A market-leading approach to client and consumer transparency further aligns incentives across patients and plan sponsors, offering consumers new affordability tools.
May 11, 2026
*As of Nov. 1, 2025